English

Sucampo Pharmaceuticals, Inc.

EDGAR

SCMP Quarterly report (10-Q) · filed 2017-11-01

49 filing records in this dataset, filed from 2007-08-22 to 2017-11-01. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

61.3 million iso4217-usd

2017 Q3 · iso4217-usd

Exact inputs and evidence

Revenue: 61266000 iso4217-usd Source

Operating margin

34.6%

2017 Q3 · %

Exact inputs and evidence

Operating Income: 21200000 iso4217-usd Source
Revenue: 61266000 iso4217-usd Source

Operating cash flow

-5.25 million iso4217-usd

2017 Q3 · iso4217-usd

Exact inputs and evidence

Operating Cash Flow: 50941000 iso4217-usd Source
Operating Cash Flow: 56192000 iso4217-usd Source

Free cash flow

-5.3 million iso4217-usd

2017 Q3 · iso4217-usd

Exact inputs and evidence

Operating Cash Flow: 50941000 iso4217-usd Source
Operating Cash Flow: 56192000 iso4217-usd Source
Capital Expenditure: 403000 iso4217-usd Source
Capital Expenditure: 354000 iso4217-usd Source

Cash and cash equivalents: 75 million iso4217-usd 2017-09-30 Source
Exact value

75041000 iso4217-usd
Long-term debt including current maturities: Not available
Shares outstanding: 42.4 million shares 2013-09-30 Source
Exact value

42389346 shares

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2017-11-01.

Financial data available through: 2016-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2016-12-31
Operating income: 4 of 11 periods available· newest 2016-12-31
Net income: 4 of 11 periods available· newest 2016-12-31
Operating cash flow: 4 of 11 periods available· newest 2016-12-31
Capital expenditure: 4 of 11 periods available· newest 2016-12-31
Total assets: 3 of 11 periods available· newest 2016-12-31
Total liabilities: 3 of 11 periods available· newest 2016-12-31
Current assets: 3 of 11 periods available· newest 2016-12-31
Current liabilities: 3 of 11 periods available· newest 2016-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2016-12-31
long term debt: No compatible figures in this window
Shares outstanding: 1 of 11 periods available· newest 2012-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+50.2%

Prior period

iso4217-usd 153.18 million

2015-01-01 – 2015-12-31
Current period

iso4217-usd 230.06 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

230056000 − 153180000 = 76876000 iso4217-usd

153180000 iso4217-usd · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
230056000 iso4217-usd · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Sucampo Pharmaceuticals, Inc. · 2016-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Year-over-year change in Revenue: 76876000 iso4217-usd Concept: fundies:Revenue Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 230056000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#926691 Filing: 000117184317001354 Input fundies:Revenue: 153180000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#926828 Filing: 000117184317001354
The citation records this snapshot. The page link may show a newer release later.
Net income
-44.6%

Prior period

iso4217-usd 33.37 million

2015-01-01 – 2015-12-31
Current period

iso4217-usd 18.49 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

18487000 − 33371000 = -14884000 iso4217-usd

33371000 iso4217-usd · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
18487000 iso4217-usd · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Sucampo Pharmaceuticals, Inc. · 2016-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Year-over-year change in Net income: -14884000 iso4217-usd Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 18487000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#639197 Filing: 000117184317001354 Input fundies:NetIncome: 33371000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#639343 Filing: 000117184317001354
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-55.3%

Prior period

iso4217-usd 18.59 million

2015-01-01 – 2015-12-31
Current period

iso4217-usd 8.31 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

8313000 − 18585000 = -10272000 iso4217-usd

18585000 iso4217-usd · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
8313000 iso4217-usd · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Sucampo Pharmaceuticals, Inc. · 2016-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Year-over-year change in Operating cash flow: -10272000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 8313000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#638466 Filing: 000117184317001354 Input fundies:OperatingCashFlow: 18585000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#638709 Filing: 000117184317001354
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-65.5%

Prior period

iso4217-usd 3.56 million

2015-01-01 – 2015-12-31
Current period

iso4217-usd 1.23 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

1226000 − 3557000 = -2331000 iso4217-usd

3557000 iso4217-usd · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
1226000 iso4217-usd · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Sucampo Pharmaceuticals, Inc. · 2016-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Year-over-year change in Capital expenditure: -2331000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1226000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#778847 Filing: 000117184317001354 Input fundies:CapitalExpenditure: 3557000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#779050 Filing: 000117184317001354
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2016 2016-01-01 – 2016-12-31

Revenue iso4217-usd 230.06 million 100% of revenue
Operating costs Derived iso4217-usd 176.18 million 77% of revenue
Operating income iso4217-usd 53.88 million 23% of revenue
Tax, interest and other Derived iso4217-usd 35.39 million 15% of revenue
Net income iso4217-usd 18.49 million 8% of revenue

Cash

Operating cash flow iso4217-usd 8.31 million 3.6% of revenue
Capital expenditure iso4217-usd 1.23 million 0.5% of revenue
Free cash flow Derived iso4217-usd 7.09 million 3.1% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 90%
2014 11%12%76%
2015 22%71%
2016 15%77%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2013-01-01 – 2013-12-31	89594000	80398000 Derived	9196000	2181000 Derived	7015000	-4377000 Derived	Source 2013-01-01 – 2013-12-31: 89594000 iso4217-usd Inspect Revenue Open source 2013-01-01 – 2013-12-31: 9196000 iso4217-usd Inspect Operating Income Open source 2013-01-01 – 2013-12-31: 7015000 iso4217-usd Inspect Net Income Open source 2013-01-01 – 2013-12-31: -4209000 iso4217-usd Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 168000 iso4217-usd Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	115450000	88219000 Derived	27231000	14103000 Derived	13128000	30812000 Derived	Source 2014-01-01 – 2014-12-31: 115450000 iso4217-usd Inspect Revenue Open source 2014-01-01 – 2014-12-31: 27231000 iso4217-usd Inspect Operating Income Open source 2014-01-01 – 2014-12-31: 13128000 iso4217-usd Inspect Net Income Open source 2014-01-01 – 2014-12-31: 30878000 iso4217-usd Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 66000 iso4217-usd Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	153180000	108721000 Derived	44459000	11088000 Derived	33371000	15028000 Derived	Source 2015-01-01 – 2015-12-31: 153180000 iso4217-usd Inspect Revenue Open source 2015-01-01 – 2015-12-31: 44459000 iso4217-usd Inspect Operating Income Open source 2015-01-01 – 2015-12-31: 33371000 iso4217-usd Inspect Net Income Open source 2015-01-01 – 2015-12-31: 18585000 iso4217-usd Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 3557000 iso4217-usd Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	230056000	176180000 Derived	53876000	35389000 Derived	18487000	7087000 Derived	Source 2016-01-01 – 2016-12-31: 230056000 iso4217-usd Inspect Revenue Open source 2016-01-01 – 2016-12-31: 53876000 iso4217-usd Inspect Operating Income Open source 2016-01-01 – 2016-12-31: 18487000 iso4217-usd Inspect Net Income Open source 2016-01-01 – 2016-12-31: 8313000 iso4217-usd Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 1226000 iso4217-usd Inspect Capital Expenditure Open source

Amounts are exact, in iso4217-usd.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

iso4217-usd 230.1M 2016

Values and sources

Revenue values and source evidence
Period	Series	Value(iso4217-usd)	Source evidence
20132013-12-31	Revenue	89594000	Revenue: 89594000 Open source
20142014-12-31	Revenue	115450000	Revenue: 115450000 Open source
20152015-12-31	Revenue	153180000	Revenue: 153180000 Open source
20162016-12-31	Revenue	230056000	Revenue: 230056000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

50.2% 2016

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Year over year	No prior comparable period	Revenue: 89594000 Open source
20142014-12-31	Year over year	28.9%	Revenue: 115450000 Open source Revenue: 89594000 Open source
20152015-12-31	Year over year	32.7%	Revenue: 153180000 Open source Revenue: 115450000 Open source
20162016-12-31	Year over year	50.2%	Revenue: 230056000 Open source Revenue: 153180000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 23.4% 2016

Net margin 8% 2016

Free cash flow margin 3.1% 2016

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Operating margin	10.3%	Operating Income: 9196000 Open source Revenue: 89594000 Open source
20142014-12-31	Operating margin	23.6%	Operating Income: 27231000 Open source Revenue: 115450000 Open source
20152015-12-31	Operating margin	29%	Operating Income: 44459000 Open source Revenue: 153180000 Open source
20162016-12-31	Operating margin	23.4%	Operating Income: 53876000 Open source Revenue: 230056000 Open source
20132013-12-31	Net margin	7.8%	Net Income: 7015000 Open source Revenue: 89594000 Open source
20142014-12-31	Net margin	11.4%	Net Income: 13128000 Open source Revenue: 115450000 Open source
20152015-12-31	Net margin	21.8%	Net Income: 33371000 Open source Revenue: 153180000 Open source
20162016-12-31	Net margin	8%	Net Income: 18487000 Open source Revenue: 230056000 Open source
20132013-12-31	Free cash flow margin	-4.9%	Revenue: 89594000 Open source Operating Cash Flow: -4209000 Open source Capital Expenditure: 168000 Open source
20142014-12-31	Free cash flow margin	26.7%	Revenue: 115450000 Open source Operating Cash Flow: 30878000 Open source Capital Expenditure: 66000 Open source
20152015-12-31	Free cash flow margin	9.8%	Revenue: 153180000 Open source Operating Cash Flow: 18585000 Open source Capital Expenditure: 3557000 Open source
20162016-12-31	Free cash flow margin	3.1%	Revenue: 230056000 Open source Operating Cash Flow: 8313000 Open source Capital Expenditure: 1226000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

iso4217-usd 8.3M 2016

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(iso4217-usd)	Source evidence
20132013-12-31	Operating cash flow	-4209000	Operating Cash Flow: -4209000 Open source
20142014-12-31	Operating cash flow	30878000	Operating Cash Flow: 30878000 Open source
20152015-12-31	Operating cash flow	18585000	Operating Cash Flow: 18585000 Open source
20162016-12-31	Operating cash flow	8313000	Operating Cash Flow: 8313000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

iso4217-usd 7.1M 2016

Values and sources

Free cash flow values and source evidence
Period	Series	Value(iso4217-usd)	Source evidence
20132013-12-31	Free cash flow	-4377000	Operating Cash Flow: -4209000 Open source Capital Expenditure: 168000 Open source
20142014-12-31	Free cash flow	30812000	Operating Cash Flow: 30878000 Open source Capital Expenditure: 66000 Open source
20152015-12-31	Free cash flow	15028000	Operating Cash Flow: 18585000 Open source Capital Expenditure: 3557000 Open source
20162016-12-31	Free cash flow	7087000	Operating Cash Flow: 8313000 Open source Capital Expenditure: 1226000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

67.9% 2016

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2013-12-31	Liabilities / assets	Not reported	No source recorded
20142014-12-31	Liabilities / assets	41.9%	Total Liabilities: 59262000 Open source Total Assets: 141574000 Open source
20152015-12-31	Liabilities / assets	81.1%	Total Liabilities: 370732000 Open source Total Assets: 457181000 Open source
20162016-12-31	Liabilities / assets	67.9%	Total Liabilities: 353752000 Open source Total Assets: 520851000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

9.5× 2016

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2013-12-31	Current assets / current liabilities	Not reported	No source recorded
20142014-12-31	Current assets / current liabilities	3.6×	Current Assets: 121848000 Open source Current Liabilities: 33810000 Open source
20152015-12-31	Current assets / current liabilities	2.85×	Current Assets: 251360000 Open source Current Liabilities: 88127000 Open source
20162016-12-31	Current assets / current liabilities	9.5×	Current Assets: 307232000 Open source Current Liabilities: 32351000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2013-01-01 – 2013-12-31	iso4217-usd 7.02 million Exact value Exact value: 7015000 iso4217-usd 2013-01-01 – 2013-12-31: 7015000 iso4217-usd Inspect Net Income Open source Share or cite Citation for Net Income · Sucampo Pharmaceuticals, Inc. · 2013-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Net Income: 7015000 iso4217-usd Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=iso4217-usd&dimensions= Input fundies:NetIncome: 7015000 iso4217-usd (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184316008620/scmp-20151231.xml#693193 Filing: 000117184316008620 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 4.21 million Exact value Exact value: -4209000 iso4217-usd 2013-01-01 – 2013-12-31: -4209000 iso4217-usd Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sucampo Pharmaceuticals, Inc. · 2013-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Operating Cash Flow: -4209000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=iso4217-usd&dimensions= Input fundies:OperatingCashFlow: -4209000 iso4217-usd (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184316008620/scmp-20151231.xml#692700 Filing: 000117184316008620 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 168,000 Exact value Exact value: 168000 iso4217-usd 2013-01-01 – 2013-12-31: 168000 iso4217-usd Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sucampo Pharmaceuticals, Inc. · 2013-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Capital Expenditure: 168000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=iso4217-usd&dimensions= Input fundies:CapitalExpenditure: 168000 iso4217-usd (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184316008620/scmp-20151231.xml#830466 Filing: 000117184316008620 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 4.38 million Calculation and evidence -4209000 − 168000 iso4217-usd Exact free cash flow: -4377000 iso4217-usd 2013-01-01 – 2013-12-31: -4209000 iso4217-usd · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 168000 iso4217-usd · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sucampo Pharmaceuticals, Inc. · 2013-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Free cash flow: -4377000 iso4217-usd Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4209000 iso4217-usd (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184316008620/scmp-20151231.xml#692700 Filing: 000117184316008620 Input fundies:CapitalExpenditure: 168000 iso4217-usd (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184316008620/scmp-20151231.xml#830466 Filing: 000117184316008620 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	iso4217-usd 13.13 million Exact value Exact value: 13128000 iso4217-usd 2014-01-01 – 2014-12-31: 13128000 iso4217-usd Inspect Net Income Open source Share or cite Citation for Net Income · Sucampo Pharmaceuticals, Inc. · 2014-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Net Income: 13128000 iso4217-usd Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=iso4217-usd&dimensions= Input fundies:NetIncome: 13128000 iso4217-usd (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#639489 Filing: 000117184317001354 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 30.88 million Exact value Exact value: 30878000 iso4217-usd 2014-01-01 – 2014-12-31: 30878000 iso4217-usd Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sucampo Pharmaceuticals, Inc. · 2014-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Operating Cash Flow: 30878000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=iso4217-usd&dimensions= Input fundies:OperatingCashFlow: 30878000 iso4217-usd (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#638953 Filing: 000117184317001354 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 66,000 Exact value Exact value: 66000 iso4217-usd 2014-01-01 – 2014-12-31: 66000 iso4217-usd Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sucampo Pharmaceuticals, Inc. · 2014-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Capital Expenditure: 66000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=iso4217-usd&dimensions= Input fundies:CapitalExpenditure: 66000 iso4217-usd (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#779253 Filing: 000117184317001354 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 30.81 million Calculation and evidence 30878000 − 66000 iso4217-usd Exact free cash flow: 30812000 iso4217-usd 2014-01-01 – 2014-12-31: 30878000 iso4217-usd · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 66000 iso4217-usd · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sucampo Pharmaceuticals, Inc. · 2014-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Free cash flow: 30812000 iso4217-usd Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 30878000 iso4217-usd (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#638953 Filing: 000117184317001354 Input fundies:CapitalExpenditure: 66000 iso4217-usd (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#779253 Filing: 000117184317001354 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	iso4217-usd 33.37 million Exact value Exact value: 33371000 iso4217-usd 2015-01-01 – 2015-12-31: 33371000 iso4217-usd Inspect Net Income Open source Share or cite Citation for Net Income · Sucampo Pharmaceuticals, Inc. · 2015-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Net Income: 33371000 iso4217-usd Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=iso4217-usd&dimensions= Input fundies:NetIncome: 33371000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#639343 Filing: 000117184317001354 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 18.59 million Exact value Exact value: 18585000 iso4217-usd 2015-01-01 – 2015-12-31: 18585000 iso4217-usd Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sucampo Pharmaceuticals, Inc. · 2015-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Operating Cash Flow: 18585000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=iso4217-usd&dimensions= Input fundies:OperatingCashFlow: 18585000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#638709 Filing: 000117184317001354 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 3.56 million Exact value Exact value: 3557000 iso4217-usd 2015-01-01 – 2015-12-31: 3557000 iso4217-usd Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sucampo Pharmaceuticals, Inc. · 2015-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Capital Expenditure: 3557000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=iso4217-usd&dimensions= Input fundies:CapitalExpenditure: 3557000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#779050 Filing: 000117184317001354 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 15.03 million Calculation and evidence 18585000 − 3557000 iso4217-usd Exact free cash flow: 15028000 iso4217-usd 2015-01-01 – 2015-12-31: 18585000 iso4217-usd · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 3557000 iso4217-usd · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sucampo Pharmaceuticals, Inc. · 2015-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Free cash flow: 15028000 iso4217-usd Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 18585000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#638709 Filing: 000117184317001354 Input fundies:CapitalExpenditure: 3557000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#779050 Filing: 000117184317001354 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	iso4217-usd 18.49 million Exact value Exact value: 18487000 iso4217-usd 2016-01-01 – 2016-12-31: 18487000 iso4217-usd Inspect Net Income Open source Share or cite Citation for Net Income · Sucampo Pharmaceuticals, Inc. · 2016-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Net Income: 18487000 iso4217-usd Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=iso4217-usd&dimensions= Input fundies:NetIncome: 18487000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#639197 Filing: 000117184317001354 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 8.31 million Exact value Exact value: 8313000 iso4217-usd 2016-01-01 – 2016-12-31: 8313000 iso4217-usd Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sucampo Pharmaceuticals, Inc. · 2016-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Operating Cash Flow: 8313000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=iso4217-usd&dimensions= Input fundies:OperatingCashFlow: 8313000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#638466 Filing: 000117184317001354 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 1.23 million Exact value Exact value: 1226000 iso4217-usd 2016-01-01 – 2016-12-31: 1226000 iso4217-usd Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sucampo Pharmaceuticals, Inc. · 2016-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Capital Expenditure: 1226000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=iso4217-usd&dimensions= Input fundies:CapitalExpenditure: 1226000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#778847 Filing: 000117184317001354 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 7.09 million Calculation and evidence 8313000 − 1226000 iso4217-usd Exact free cash flow: 7087000 iso4217-usd 2016-01-01 – 2016-12-31: 8313000 iso4217-usd · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 1226000 iso4217-usd · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sucampo Pharmaceuticals, Inc. · 2016-12-31 Sucampo Pharmaceuticals, Inc. (edgar:1365216) Free cash flow: 7087000 iso4217-usd Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:42:30Z Snapshot: 457324b801dc8216619b2faf80fd25308077074b6a8262aaf4eb9d240629fbc3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1365216?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 8313000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#638466 Filing: 000117184317001354 Input fundies:CapitalExpenditure: 1226000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1365216/000117184317001354/scmp-20161231.xml#778847 Filing: 000117184317001354 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

49 filings · 3,199 latest values · 3,199 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001365216, 1365216, SCMP, edgar:1365216, scmp

Also known as SUCAMPO PHARMACEUTICALS, INC., Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2016 2016-01-01 – 2016-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation